
Keywords: ADT; androgen deprivation therapy; AR; androgen receptor; ASO; antisense oligonucleotide; CARN; castration-resistant Nkx3.1 expressing cells; CK; cytokeratin; CRPC; castration-resistant prostate cancer; DMBA; 7,12-dimethylbenz[a]anthracene; ECM; extracell